Investor Presentaiton
Repositioning TCB-008; Best-in-Class for Combination Therapies
TCB-008 will be focused as a "best-in-class" allogeneic gamma delta variant 2 product
■ TCB-008 has an ideal profile for combination therapies
- No drug related toxicity
-
Allogeneic, should not cause drug on drug interaction
- Chemo resistant when activated
■TCBP has the internal capability to deliver a Best-in-Class allogeneic gammal
delta t-cell (GMP grade or non-GMP grade) for use in clinical trials and
research
Company focus for TCB-008 will be on multiple exclusive
partnerships/agreements for TCB-008 in Combination trials
-
Upfront payments, non-dilutive with royalty agreements
- Exclusive supplier agreements for GDT v2
Companies claiming to turn the "cold tumor hot" or "light the tumor" to
gamma deltas in cancer patients
■ Inherent issue in immune suppressed,/immune compromised patients will
be the lack of gamma delta population or very inert gammas
■To maximize the effect of the "trigger" asset, exogenous gamma deltas will be
necessary.
14
TC
BIOPHARMView entire presentation